Loading
Defined the molecular subtypes of breast cancer (luminal, HER2-enriched, basal-like) that clinicians now use every day.
Charles Perou led the 2000 Nature paper that used expression profiling to divide breast cancer into intrinsic subtypes, the classification that introduced basal-like disease and underpins triple-negative research. He developed the PAM50 assay that became Prosigna and co-led the TCGA breast cancer analysis. His lab continues to map breast tumour heterogeneity and immune microenvironments.
Cancers are defined as much by the tissue they come from as by the mutations they carry, which is why the same drug can work in one organ and fail in another with the same mutation. TCGA is the shared public dataset behind most modern biomarkers and target discovery.
With GeparSixto, the trial that put carboplatin into the neoadjuvant triple-negative regimen; KEYNOTE-522's chemotherapy backbone is this one plus pembrolizumab. Bevacizumab, the other arm, left the field.
This is the reference frequency table for basal-like disease: it explains why PARP inhibitors and platinum, borrowed from ovarian cancer, work in TNBC, and why the PI3K pathway is broken by copy number rather than the hotspot mutations that drugs were designed against.
Functional RB1 loss is part of basal-like biology, which explains why CDK4/6 inhibitors have not worked in TNBC and why the cell-cycle vulnerability there lies downstream of RB.
The paper that made race a biological as well as a social variable in triple-negative breast cancer, and the reason the US disparity is described as roughly twice the incidence in Black women; the UK POSH study later found a smaller but real excess.
The molecular bridge between germline BRCA1 and triple-negative breast cancer; it is why every triple-negative patient under 60 is now offered germline testing and why PARP inhibitors were tried in this disease first.
The first evidence that the basal-like group is not just biologically distinct but clinically dangerous, the observation that triple-negative outcome studies of 2007 confirmed in the clinic.
The origin of the intrinsic subtypes and of the word basal-like; triple-negative breast cancer is the clinical shadow of this molecular group, though the two overlap imperfectly.
Shares RNA sequencing & expression profiling, HER2-positive breast cancer, Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer and the tags breast, genomics, classification.
Shares RNA sequencing & expression profiling, HER2-positive breast cancer, HR-positive / HER2-negative breast cancer and the tags breast, genomics.
Shares Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications, Repeated observation of breast tumor subtypes in independent gene expression data sets, Molecular portraits of human breast tumours, Comprehensive molecular portraits of human breast tumours.
Shares Repeated observation of breast tumor subtypes in independent gene expression data sets, Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study, Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem, Triple-negative breast cancer (TNBC).
Shares TCGA Pan-Cancer Atlas: 10,000 tumours across 33 cancer types, classified by molecular features, Companion diagnostics and the tag genomics.
Shares HER2-positive breast cancer, Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer and the tag breast.
Shares HER2-positive breast cancer, Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer and the tag breast.
Shares HER2-positive breast cancer, Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer and the tag breast.